Activity in this selectionBiotech
- Rounds participated in
- 2
- Confirmed lead rounds
- 0
1 roles undisclosed- New companies
- 2
First participation on record · 0 follow-on- Funding in participating rounds
- $59.8M
1 disclosed · full round size, not this investor’s share
Rounds
2 in this selectionNouscomClinical-stage biotech developing neoantigen-based cancer immunotherapies.
ParticipantExcivaDevelops novel therapies for behavioral symptoms associated with Alzheimer's Disease
Role not disclosed